Bright Minds Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRUG research report →
About the company
Bright Minds Biosciences Inc. , a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
- CEO
- Ian McDonald
- IPO
- 2021
- Employees
- 26
- HQ
- New York, NY, CA
Price Chart
- Market Cap
- $524.68M
- P/E
- -28.11
- P/S
- 0.00
- P/B
- 2.97
- EV/EBITDA
- -13.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -20.73%
- ROIC
- -10.20%
- Revenue
- $0 · 0.00%
- Net Income
- $-12,229,348 · -336.46%
- EPS
- $-1.78 · -173.85%
- Op Income
- $-13,937,584
- FCF YoY
- -369.77%
- 52W High
- $123.75
- 52W Low
- $24.00
- 50D MA
- $76.69
- 200D MA
- $73.79
- Beta
- 0.10
- Avg Volume
- 294.64K
Get TickerSpark's AI analysis on DRUG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Cormorant Asset Management, LP | sell | 109,331 |
| Nov 4, 24 | Cormorant Asset Management, LP | buy | 184,331 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 3,107 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 7,150 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 39,743 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 4,609 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 19,169 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 2,700 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 2,600 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 8,900 |
Our DRUG coverage
Recent articles, reports, and earnings notes.
No research on DRUG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRUG report →Similar companies
Peers in the same neighborhood.